Home - Products - Others - Other Targets - 4-hydroxy-3-methylbenzoic acid

4-hydroxy-3-methylbenzoic acid

CAS No. 499-76-3

4-hydroxy-3-methylbenzoic acid( 43-Cresotic acid )

Catalog No. M20003 CAS No. 499-76-3

4-Hydroxy-3-methylbenzoic acid is a normal organic acid identified in urine specimens from a healthy population.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 37 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    4-hydroxy-3-methylbenzoic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    4-Hydroxy-3-methylbenzoic acid is a normal organic acid identified in urine specimens from a healthy population.
  • Description
    4-Hydroxy-3-methylbenzoic acid is a normal organic acid identified in urine specimens from a healthy population.
  • In Vitro
    4-Hydroxy-3-methylbenzoic acid was isolated as the product of oxidation of 2,4-xylenol by cells inhibited with alpha alpha'-bipyridyl.
  • In Vivo
    ——
  • Synonyms
    43-Cresotic acid
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    499-76-3
  • Formula Weight
    152.15
  • Molecular Formula
    C8H8O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:200 mM
  • SMILES
    Cc1cc(ccc1O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Guneral F et al. Age-related reference values for urinary organic acids in a healthy Turkish pediatric population. Clin Chem. 1994 Jun;40(6):862-6.
molnova catalog
related products
  • Bergaptol

    Bergaptol is a potent inhibitor of debenzylation activity of CYP3A4 enzyme.

  • Rituximab

    Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.

  • Gelsemine

    Gelsemine has marked antinociception in inflammatory, neuropathic and bone cancer pains without inducing antinociceptive tolerance.